JACN Did you know that you can get alerts when a new issue is online?
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Figures Only
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kumar, B.
Right arrow Articles by Prasad, K. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kumar, B.
Right arrow Articles by Prasad, K. N.
Journal of the American College of Nutrition, Vol. 21, No. 4, 339-343 (2002)
Published by the American College of Nutrition

D-Alpha-Tocopheryl Succinate (Vitamin E) Enhances Radiation-Induced Chromosomal Damage Levels in Human Cancer Cells, but Reduces it in Normal Cells

Bipin Kumar, MD, Mitra N. Jha, William C. Cole, PhD, Joel S. Bedford, DPhil and Kedar N. Prasad, PhD, FACN

Center for Vitamins and Cancer Research, Department of Radiology, University of Colorado Health Sciences Center, Denver (B.K., W.C., K.P.), Colorado
Department of Radiological Health Sciences, Colorado State University, Fort Collins (M.N.J., J.S.B.), Colorado

Address reprint requests to: Kedar N. Prasad, Ph.D., University of Colorado Health Sciences Center, 4200 East 9th Ave, Denver, CO 80262-0278. E mail: Kedar.Prasad{at}UCHSC.edu


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 CONCLUSION
 ACKNOWLEDGMENTS
 REFERENCES
 
Objective: The purpose of this study was to measure and compare the effect of d-{alpha}-tocopheryl succinate ({alpha}-TS) in modifying radiation-induced chromosomal damage in human normal cells and cancer cells in culture.

Methods: Three human normal fibroblast cell lines (GM2149, AG1522 and HF19) and three human cancer cell lines, cervical cancer (HeLa) and ovarian carcinoma cells (OVG1 and SKOV3) were treated with {alpha}-TS (37.6 µM) 20 hours before 100 cGy {gamma}-irradiation. After 30 minutes of irradiation, colcemid was added and cells were fixed. One hundred randomly selected metaphase cells were scored for the presence of chromatid gaps and breaks. To study the cellular accumulation of {alpha}-TS, cells were incubated in the presence of {alpha}-TS (18.8 and 37.6 µM) for 24 hours, and {alpha}-TS was extracted with hexane using {alpha}-tocopheryl acetate as an internal standard. The levels of {alpha}-TS were determined by HPLC.

Results: Results showed that {alpha}-TS induced chromosomal damage in both human cervical cancer cells and ovarian cancer cells, but not in human normal fibroblasts in culture. In addition, {alpha}-TS enhanced the level of radiation-induced chromosomal damage in cancer cells, but it protected normal cells against such damage. Both cancer cells and normal cells accumulated similar levels of {alpha}-TS, suggesting that increased sensitivity of cancer cells to {alpha}-TS is acquired during transformation.

Conclusion: The use of {alpha}-TS during radiation therapy may improve the efficacy of radiation therapy by enhancing tumor response and decreasing some of the toxicities on normal cells.

Key words: irradiation, radiation therapy, carcinoma, chromatid damage


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 CONCLUSION
 ACKNOWLEDGMENTS
 REFERENCES
 
Several studies on the radioprotective effects of vitamin E on normal cells in animals have been published [1–9]. We have reported that {alpha}-tocopheryl succinate ({alpha}-TS), the most effective form of vitamin E [10,11], enhances the growth-inhibitory effect of x-irradiation on neuroblastoma cells in culture [12]. Recently, we have shown that {alpha}-TS increases the levels of radiation-induced decrease in mitotic accumulation in human cervical carcinoma cells and ovarian carcinoma cells in culture, but it does not modify this effect of irradiation in normal fibroblasts in culture [13]. Ionizing radiation is well known to induce chromosomal damage in both normal and cancer cells; however, it is unknown whether {alpha}-TS can modify this effect of irradiation in cancer cells and normal cells. It is also unknown whether {alpha}-TS-induced damage in cancer cells is due to increased accumulation of {alpha}-TS in these cells.

We now report that {alpha}-TS by itself induces chromosomal damage in cancer cells, but not in normal cells in culture. In addition, it enhances the levels of {gamma}-irradiation-induced chromosomal damage in cancer cells, whereas it protects normal cells against such damage. Both normal and cancer cells accumulate similar levels of {alpha}-TS, suggesting that increased sensitivity of cancer cells to {alpha}-TS is acquired during transformation.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 CONCLUSION
 ACKNOWLEDGMENTS
 REFERENCES
 
Cell Culture
Human cervical carcinoma cells (HeLa cells from Dr. L.J Tolmach) ovarian carcinoma cells (OVG1 from Drs J.B. Mitchell and J.A. Cook, and SKOV3 from Dr. L. Smith) and human normal skin fibroblasts (GM 2149 from the NIGMS Human Genetic Mutant Cell Repository, AG1522 from the NIA Cell Repository and HF19 from Dr. D. Goodhead) were grown in culture as described earlier [13].

Treatment of Cells and Assay of Chromosomal Damage
The procedures for making solutions of d-{alpha}-tocopheryl succinate (Henkel, Chicago), colcemid (Sigma, St. Louise) and their storage have been published earlier [13]. In brief, {alpha}-TS was dissolved in ethanol at a concentration of 5 mg/mL. Cells were treated with {alpha}-TS (20 µg/ml or 37.6 µM) for 20 hours before {gamma}-irradiation (100 cGy). The above concentration of {alpha}-TS and treatment period were selected because this concentration under the above experimental conditions inhibits the growth of cancer cells, but not of normal fibroblasts in culture [13]. It has been shown that a daily oral intake of 800 IU {alpha}-TS increases plasma levels of vitamin E ({alpha}-tocopherol, 60 µg/mL and {alpha}-TS, 6 µg/mL) [14]. The basal level of {alpha}-tocopherol in plasma is about 6–10 µg/mL. After 30 minutes of irradiation, colcemid (0.1 µg/ml) was added and one hour later the cells were fixed with 3:1 methanol and acetic acid for an hour and stained with Giemsa. The slides were randomized and coded to ensure that the observer was unaware of conditions of treatment at the time of scoring the chromosomal damage. For aberration frequency, 100 randomly selected metaphase-like cells were scored for the presence of chromosomal aberrations (chromatid gaps and breaks) according to the criterion suggested by Savage [15].

Intracellular Uptake of A-TS
To study the uptake of {alpha}-TS by cancer cells and normal cells, cells were incubated in the presence of {alpha}-TS (18.8 and 36.6 µM) for 24 hours and then removed and washed with PBS. Vitamin E was extracted with hexane using {alpha}-tocopheryl acetate ({alpha}-TA) as an internal standard. The levels of {alpha}-TS and {alpha}-TA were determined by HPLC using a C18 column (4.6 mm x 250 mm, 5 µm particle size) eluted with acetonitrile:MeOH (0.028% TFA) 60:40 (v/v) at a flow rate of 2.0 mL/minute. The level of each form of vitamin E was determined from a standard curve and expressed as µg of vitamin E/mg protein. Protein was determined by the method of Lowry et al. [16].

Statistical Analysis
Each experiment was repeated twice. The significant difference between control and experimental groups was determined by one-tail Student’s t test at p = 0.05.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
CONCLUSION
 ACKNOWLEDGMENTS
 REFERENCES
 
Results showed that treatment with {alpha}-TS (20 µg/mL or 37.6 µM) for a period of 20 hours increased the level of chromosomal damage (chromatid gaps and breaks) in HeLa cells and ovarian carcinoma cells, but not in three lines of normal human fibroblasts (Fig. 1). Solvent treatment did not alter chromosomal damage in cancer cells or normal fibroblasts in comparison to untreated control cells (data not shown). In cancer cell lines, the differences between untreated or solvent treated control and {alpha}-TS treated cells were significant at p < 0.05. In addition, {alpha}-TS treatment 20 hours before {gamma}-irradiation enhanced the level of radiation-induced chromosomal damage in all tumor cell lines. On the other hand, a similar treatment with {alpha}-TS reduced radiation-induced chromosomal damage in all normal human fibroblast cell lines (Fig. 1). Solvent treatment did not alter radiation-induced chromosomal damage either in cancer cells or normal fibroblasts (data not shown). In both cancer cells and normal fibroblasts, the differences between irradiated cells and cells treated with {alpha}-TS and irradiation were significant at p < 0.05. It should be pointed out that all cancer cell lines are of epithelial origin; therefore, the observations made on fibroblasts may or may not be relevant to normal human epithelial cells.



View larger version (26K):
[in this window]
[in a new window]
  		Fig. 1. Effect of d-{alpha}-tocopheryl succinate ({alpha}-TS) on the level of radiation-induced chromosomal damage in human cervical cancer (HeLa cells), ovarian carcinoma cell lines (OVG1 and SKOV3) and in human normal skin fibroblasts (GM2149, HF19 and AG1522). {alpha}-TS treatment alone increased chromosomal damage in all three cancer cell lines, but not in any normal cell lines. {alpha}-TS treatment also enhanced the levels of radiation-induced chromosomal damage in cancer cells but it protected normal cells against such damage. The bar is standard error of the mean; the difference between control and experimental groups in cancer cells, and between control (irradiation alone) and experimental groups (irradiation plus {alpha}-TS) is significant at p < 0.05.

 
In order to establish whether the higher sensitivity of cancer cells to {alpha}-TS is related to the increased accumulation of this vitamin E, the levels of {alpha}-TS in cancer cells and normal fibroblasts were determined by HPLC after incubation of cells in the presence of 18.8 or 37.6 µM of {alpha}-TS for 24 hours at 37°. Results showed that HeLa cells and normal cells after 24 hours of incubation accumulated similar levels of {alpha}-TS (Table 1). The level of {alpha}-TS was undetectable in both cancer cells and normal fibroblasts, suggesting that these cells do not convert {alpha}-TS to {alpha}-tocopherol in any significant amounts within 24 hours. These results indicate that increased sensitivity of cancer cells to {alpha}-TS is acquired during transformation and is not due to enhanced accumulation of this form of vitamin E.


View this table:
[in this window]
[in a new window]
  		Table 1. Accumulation of D-{alpha}-Tocopheryl Succinate ({alpha}-TS) in Human Cervical Cancer (HeLa cells) and Normal Human Fibroblasts after 24 Hours of Treatment with {alpha}-TS

 

   DISCUSSION
 
The present study shows that {alpha}-TS treatment induces chromosomal damage in cancer cells, but not in normal cells. This selective effect of {alpha}-TS on human cancer cells is consistent with the results published earlier by us and others on other criteria of damage [10,11,14,17–20] and in animal tumor models [21,22]. To determine whether the increased sensitivity of cancer cells to {alpha}-TS is related to the enhanced accumulation of this form of vitamin E in these cells, cancer cells and normal fibroblasts were incubated in the presence of {alpha}-TS for 24 hours, and cellular levels of {alpha}-TS were determined by HPLC. Results showed that both cancer cells and normal cells accumulated similar levels of {alpha}-TS. This suggests that the increased sensitivity of cancer cells to {alpha}-TS in comparison to normal cells is acquired during transformation.

When {alpha}-TS is given before irradiation it increases the level of radiation-induced chromosomal damage in human cervical carcinoma and ovarian carcinoma, but protects normal human fibroblasts against such damage. Solvent treatment does not modify radiation damage either in cancer cells or normal fibroblasts in culture. The radiosensitizing effect of {alpha}-TS is consistent with the results published earlier, in which treatment of tumor cells with {alpha}-TS before x-irradiation enhances the level of radiation-induced growth inhibition [12] and radiation-induced decrease in mitotic accumulation [13]. The radioprotective effect of {alpha}-TS on normal cells is also consistent with several studies reported earlier with other forms of vitamin E [1–9]. Most of these studies have focused on investigating the effect of vitamin E in modifying radiation response either in normal cells or in cancer cells. The present study is unique in the sense that it has compared the effect of {alpha}-TS in modifying radiation response on cancer cells and normal cells under similar experimental conditions. It should be pointed out that tumor cells used in this study are of epithelial origin, whereas normal cells are fibroblasts. Nevertheless, fibroblasts are also damaged during radiation therapy; therefore, if similar observations are made in vivo, the use of {alpha}-TS may improve the efficacy of radiation therapy by increasing tumor response and decreasing some of the toxicities.

Other antioxidant micronutrients such as vitamin C [23,24], all-trans-retinoic acid [25,26], retinyl palmitate (vitamin A) and ß-carotene [27] when given before irradiation also enhanced radiation-induced growth inhibition in tumor cells in culture and in vivo without causing toxicity to normal cells in vivo. A recent study has reported that administration of multiple antioxidants (vitamin A, E and C) before and after radio-immunotherapy reduced the magnitude of myelosuppression without interfering with its efficacy on tumor cells [28]. Another study has shown that vitamin C, vitamin E acetate and ß-carotene in combination with mitomycin and irradiation were more effective in reducing the growth human of leukemic cells (HL-60) in culture than the individual agents [29]. Limited clinical trials in humans have reported enhancement of the efficacy of radiation therapy and chemotherapy with antioxidant micronutrients in patients with small-cell lung carcinoma [30,31] and breast cancer [32].

The exact mechanisms of differential modification of the effect of irradiation by {alpha}-TS on chromosomal damage in normal and cancer cells are unknown. We propose that an administration of {alpha}-TS at high doses before irradiation initiates damage in cancer cells as evidenced by the alterations in expression of those genes and cell signaling systems that are involved in regulation of growth and differentiation [11,17–21,33–37]. They include decreased expression of c-myc, N-myc, H-ras, mutated p53, tumor necrosis factor, transcriptional factor E2F and Fas, and reduced activity of protein kinase C. They also include increased expression of wild type p53, p21, transforming growth factor ß (TGF-ß), and the connexin gene, and activation of caspase. Since retinoic acid has been shown to reduce the repair of potential lethal damage [25], it is possible that {alpha}-TS may have similar effects on the repair of radiation damage in cancer cells. In addition, cancer cells, in general, have lower intracellular pH than normal cells; therefore, {alpha}-TS may not be able to perform its antioxidant function. This would then allow free radicals generated during irradiation to increase damage in cancer cells initiated by {alpha}-TS. In contrast to cancer cells, {alpha}-TS does not cause any chromosomal damage in normal cells, and at normal intracellular pH, {alpha}-TS continues to perform its antioxidant action. It is also possible that {alpha}-TS may enhance the rate of repair of potential radiation damage in normal cells. Therefore, it is not surprising that {alpha}-TS protects normal cells against radiation-induced chromosomal damage.


   CONCLUSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 CONCLUSION
ACKNOWLEDGMENTS
 REFERENCES
 
The role of antioxidant micronutrients in modifying radiation damage of cancer cells has generated extensive debates. At present, most radiation oncologists do not recommend such micronutrient supplements to their patients during radiation therapy, believing that antioxidants may protect both normal and cancer cells against radiation damage, since about two-third of radiation damage is mediated via free radicals. This belief has emerged from extrapolation of the results obtained on endogenously made antioxidants such as SH-compounds and their derivatives [1,2,38], and overexpression of certain antioxidant enzymes such as mitochondrial superoxide dismutase [39,40] which protect cancer cells against radiation damage to dietary antioxidant micronutrients such as vitamins A, C and E, and carotenoids which enhance the effect of irradiation on cancer cells [10–14,17–27]. The above belief is also maintained due to extrapolation of the results obtained on the radioprotective effect of vitamins A, C and E, and carotenoids on normal cells [1–9] to cancer cells which exhibit increased radiation damage in the presence of these micronutrients. In fact many in vitro studies, some animal studies and a few human studies show that supplementation with these micronutrients before radiation therapy may increase the efficacy of this treatment by increasing tumor response and decreasing some of the toxicities on normal cells [14,41]. Well-designed clinical trials with multiple micronutrients, which include high dose antioxidants such as vitamins A, C and E, and carotenoids, are needed to substantiate the above hypothesis.


   ACKNOWLEDGMENTS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 CONCLUSION
 ACKNOWLEDGMENTS
REFERENCES
 
This study was supported by Shafroth Memorial Fund.

Received July 19, 2001. Accepted September 28, 2001.


   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 CONCLUSION
 ACKNOWLEDGMENTS
 REFERENCES
 

  1. Prasad KN: "Handbook of Radiobiology," 2nd ed. Boca Raton, FL: CRC Press,1995 .
  2. Thomson J: "Radiation Protection in Mammals." New York: Reinhold,1962 .
  3. Srinavasan V, Jacobs AL, Simpson SA, Weiss JF: Radioprotection by vitamin E. Effect on hepatic enzymes, delayed type hypersensitivity and post-irradiation survival in mice. In Meyskens FLJ, Prasad KN, (eds): "Modulation and Mediations of Cancer Cells by Vitamins." Basel: Karger, pp119 –131,1983 .
  4. Malick MA, Roy RM, Steinberg J: Effect of vitamin E on post-irradiation death in mice. Experientia34 :1216 –1217,1978 .[Medline]
  5. Londer HM, Myers CE: Radioprotective effects of vitamin E. Am J Clin Nutr31 :705a ,1978 .
  6. Delanian S: Striking regression of radiation-induced fibrosis by a combination of pentoxifylline and tocopherol. Br J Radiol71 :892 –894,1998 .[Abstract]
  7. Konopacka M, Widel M, Rzeszowska-Wolny J: Modifying effect of vitamins C, E and beta-carotene against gamma-ray-induced DNA damage in mouse cells. Mutat Res417 :85 –94,1998 .[Medline]
  8. Mutlu-Turkoglu U, Erbil Y, Oztezcan S, Olgac V, Toker G, Uysal M: The effect of selenium and/or vitamin E treatments on radiation-induced intestinal injury in rats. Life Sci66 :1905 –1913,2000 .[Medline]
  9. Weiss JF, Landauer MR: Radioprotection by antioxidants. Ann N Y Acad Sci899 :44 –60,2000 .[Abstract/Free Full Text]
  10. Prasad KN, Edwards-Prasad J: Effect of tocopherol (vitamin E) acid succinate on morphological alterations and growth inhibition in melanoma cells in culture. Cancer Res42 :550 –555,1982 .[Abstract/Free Full Text]
  11. Kline K, Yu W, Zhao B: Vitamin E succinate: Mechanisms of action as tumor cell growth inhibitor. In Prasad K, Santamaria L, Williams R (eds): "Nutrients in Cancer Prevention and Treatment." New Jersey: Humana Press, pp39 –55,1995 .
  12. Sarria A, Prasad KN: DL-alpha tocopheryl succinate enhances the effect of gamma-irradiation on neuroblastoma cells in culture. Proc Soc Exp Biol Med175 :88 –92,1984 .[Abstract]
  13. Jha MN, Bedford JS, Cole WC, Edwards-Prasad J, Prasad KN: Vitamin E (d-a tocopheryl succinate) decreases mitotic accumulation in g-irradiated human tumor, but not in normal cells. Nutr Cancer35 :189 –194,1999 .[Medline]
  14. Prasad KN, Kumar A, Kochupillai MD, Cole WC: High doses of multiple antioxidant vitamins: Essential ingredients in improving the efficacy of standard cancer therapy. J Am Coll Nutr18 :13 –25,1999 .[Abstract/Free Full Text]
  15. Savage JRK: Classification and relationship of induced chromosomal structural changes. J Med Genetics12 :103 –122,1955 .
  16. Lowry OH, Rosebrough NJ, Farr AL: Protein measurement with the folin phenol reagent. J Biol Chem193 :265 –275,1951 .[Free Full Text]
  17. Yu W, Israel K, Liao QY, Aldaz CM, Sanders BG, Kline K: Vitamin E succinate (VES) induces Fas sensitivity in human breast cancer cells: role for Mr 43,000 Fas in VES-triggered apoptosis. Cancer Res59 :953 –961,1999 .[Abstract/Free Full Text]
  18. Turley JM, Fu T, Ruscetti FW, Mikovits JA, Bertolette 3rd DC, Birchenall-Roberts MC: Vitamin E succinate induces Fas-mediated apoptosis in estrogen receptor-negative human breast cancer cells. Cancer Res57 :881 –890,1997 .[Abstract/Free Full Text]
  19. Turley J, Ruscetti F, Kim S-J, Fu T: Vitamin E succinate inhibits proliferation of BT-20 human breast cancer cells: Increased binding of cyclic AMP negatively regulates E2F transactivation activity. Cancer Res57 :2668 –2675,1997 .[Abstract/Free Full Text]
  20. Israel K, Yu W, Sanders BG, Kline K: Vitamin E succinate induces apoptosis in human prostate cancer cells: role for Fas in vitamin E succinate-triggered apoptosis. Nutr Cancer36 :90 –100,2000 .[Medline]
  21. Schwartz JL: Molecular and biochemical control of tumor growth following treatment with carotenoids or tocopherols. In Prasad KN, Santamaria L, Williams RM (eds): "Nutrients in Cancer Prevention and Treatment." New Jersey: Humana Press, pp287 –316,1995 .
  22. Malafa MP, Neitzel LT: Vitamin E succinate promotes breast cancer dormancy and inhibits VEGF gene expression [Conference Paper]. International Congress on Frontiers in Pharmacology and Therapeutics in 21st Century. New Delhi, 1st–4th December,1999 .
  23. Koch CJ, Biaglow JE: Toxicity, radiation sensitivity modification, and metabolic effects of dehydroascorbate and ascorbate in mammalian cells. J Cell Physiol94 :299 –306,1978 .[Medline]
  24. Tewfik FA, Tewfik HH, Riley EF: The influence of ascorbic acid on the growth of solid tumors in mice and on tumor control by X-irradiation. Int J Vitam Nutr Res23[Suppl] :257 –63,1982 .
  25. Rutz H, Little J: Modification of radiosensitivity and recovery from x-ray damage in vitro, by retinoic acid. Int J Radiat Oncol Biol Phys16 :1285 –1288,1981 .
  26. Kim JH, Kim SH, He SQ, Dragovic J, Brown S: Vitamins as adjuvant to conventional cancer therapy. In Prasad KN, Santamaria L, Williams RM (eds): "Nutrients in Cancer Prevention and Treatment." Totawa, NJ: Humana Press, pp363 –372,1995 .
  27. Seifter E, Rettura A, Padawar J, Levenson SM: Vitamin A and ß-carotene as adjunctive therapy to tumor excision, radiation therapy and chemotherapy. In Prasad KN (ed): "Vitamins, Nutrition and Cancer." Basel: Karger, pp1 –19,1984 .
  28. Blumenthal RD, Lew W, Reising A, Soyne D, Osorio L, Ying Z, Goldenberg DM: Anti-oxidant vitamins reduce normal tissue toxicity induced by radio-immunotherapy. Int J Cancer86 :276 –280,2000 .[Medline]
  29. Kammerer C, Czermak I, Getoff N, Kodym R: Enhancement of mitomycin C efficiency by vitamin C, E-acetate and beta-carotene under irradiation. A study in vitro. Anticancer Res19 :5319 –5321,1999 .[Medline]
  30. Lamson DW, Brignall MS: Antioxidants in cancer therapy; their actions and interactions with oncologic therapies. Alt Med Rev4 :304 –329,1999 .
  31. Jaakkola K, Lahteenmaki P, Laakso J, Harju E, Tykka H, Mahlberg K: Treatment with antioxidant and other nutrients in combination with chemotherapy and irradiation in patients with small-cell lung cancer. Anticancer Res12 :599 –606,1992 .[Medline]
  32. Folkers K, Brown R, Judy WV, Morita M: Survival of cancer patients on therapy with coenzyme Q10. Blochem Biophys Res Commun192 :241 –245,1993 .
  33. Prasad KN, Cohrs RJ, Sharma OK: Decreased expressions of c-myc and H-ras oncogenes in vitamin E succinate induced morphologically differentiated murine B-16 melanoma cells in culture. Biochem Cell Biol68 :1250 –1255,1990 .[Medline]
  34. Cohrs RJ, Torelli S, Prasad KN, Edwards-Prasad J, Sharma OK: Effect of vitamin E succinate and a cAMP-stimulating agent on the expression of c-myc and N-myc and H-ras in murine neuroblastoma cells. Int J Dev Neurosci9 :187 –194,1991 .[Medline]
  35. Nakamura T, Goto M, Matsumoto A, Tanaka I: Inhibition of NF-kappa B transcriptional activity by alpha-tocopheryl succinate. Biofactors7 :21 –30,1998 .[Medline]
  36. Chinery R, Brockman JA, Peeler MO, Shyr Y, Beauchamp D, Coffey RJ: Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: A p53-independent induction of p21WAFI/CIPI via C/EBPb. Nat Med3 :1233 –1241,1997 .[Medline]
  37. Neuzil J, Svensson I, Weber T, Weber C, Brunk UT: Alpha-tocopheryl succinate-induced apoptosis in Jurkat T cells involves caspase-3 activation, and both lysosomal and mitochondrial destabilisation. FEBS Lett445 :295 –300,1999 .[Medline]
  38. Sinclair WK: Cysteamine: differential x-ray protective effect on Chinese hamster cells during the cell cycle. Science159 :442 –444,1968 .[Abstract/Free Full Text]
  39. Sun J, Chen Y, Li M, Ge Z: Role of antioxidant enzymes on ionizing radiation resistance. Free Radical Biol Med24 :586 –593,1998 .[Medline]
  40. Motoori S, Mazima H, Ebara M, Kato H, Hirai F, Kakinuma S, Yamaguchi C, Ozawa T, Nagano T, Tsujii H, Saisho H: Overexpression of mitochondrial manganese superoxide dismutase protects against radiation-induced cell death in the human hepatocellular carcinoma cell line HLE. Cancer Res61 :5382 –5388,2001 .[Abstract/Free Full Text]
  41. Prasad K, Cole W, Prasad K: Scientific rationale for using high-dose multiple micronutrients as an adjunct to standard and experimental therapies. J Am Coll Nutr20[Suppl] :450S –463S,2001 .[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 JCOHome page
K. N. Prasad and W. C. Cole
Antioxidants in Cancer Therapy
J. Clin. Oncol., February 20, 2006; 24(6): e8 - e9.
[Full Text] [PDF]

Home page
 JCOHome page
I. Bairati, F. Meyer, M. Gelinas, A. Fortin, A. Nabid, F. Brochet, J.-P. Mercier, B. Tetu, F. Harel, B. Abdous, et al.
Randomized Trial of Antioxidant Vitamins to Prevent Acute Adverse Effects of Radiation Therapy in Head and Neck Cancer Patients
J. Clin. Oncol., August 20, 2005; 23(24): 5805 - 5813.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
K N Prasad
Rationale for using multiple antioxidants in protecting humans against low doses of ionizing radiation
Br. J. Radiol., June 1, 2005; 78(930): 485 - 492.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
K. N. Prasad
Multiple Dietary Antioxidants Enhance the Efficacy of Standard and Experimental Cancer Therapies and Decrease Their Toxicity
Integr Cancer Ther, December 1, 2004; 3(4): 310 - 322.
[Abstract] [PDF]

Home page
 Br. J. Radiol.Home page
K N Prasad, W C Cole, and G M Haase
Radiation protection in humans: extending the concept of as low as reasonably achievable (ALARA) from dose to biological damage
Br. J. Radiol., February 1, 2004; 77(914): 97 - 99.
[Full Text] [PDF]

Home page
 J. Am. Coll. Nutr.Home page
K. N. Prasad, B. Kumar, X.-D. Yan, A. J. Hanson, and W. C. Cole
{alpha}-Tocopheryl Succinate, the Most Effective Form of Vitamin E for Adjuvant Cancer Treatment: A Review
J. Am. Coll. Nutr., April 1, 2003; 22(2): 108 - 117.
[Abstract] [Full Text]

This Article
Right arrow Abstract Freely available
Right arrow Figures Only
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kumar, B.
Right arrow Articles by Prasad, K. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kumar, B.
Right arrow Articles by Prasad, K. N.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS